Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Neoplasm of Uncertain Histogenesis — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Special Category
Neoplasm of Uncertain Histogenesis

Cancer

Neoplasm of Uncertain Histogenesis

CI-CAN-00000034Explore in graph →

Non-malignant20,280 active trials259 approved drugs3,813 evidence items

NCIt: C6974
OncoTree: MBT
UMLS CUI: C1334936

Overview
Statistics
Survival
Genomics465
Variants & evidence3813
Drugs427
Trials91351
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (4,399)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 4,051–4,075 of 4,399 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.
· Clin Cancer Res · 2012 · PMID 22912387 · validated civic_curation pubmed
BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.
· Oncotarget · 2015 · PMID 26397223 · validated civic_curation pubmed
A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.
· Cancer Discov · 2014 · PMID 24631838 · validated civic_curation pubmed
Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapy-induced apoptosis.
· J Natl Cancer Inst · 2002 · PMID 11792751 · validated civic_curation pubmed
Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.
· Chem Biol Drug Des · 2011 · PMID 22034911 · validated civic_curation pubmed
Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
· JAMA Otolaryngol Head Neck Surg · 2015 · PMID 25855885 · validated civic_curation pubmed
The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines.
· Melanoma Res · 2003 · PMID 12777976 · validated civic_curation pubmed

Showing 4,051–4,075 of 4,399 publications

← Previous
1
…
162
163
164
…
176
Next →

SF3B1 mutations constitute a novel therapeutic target in breast cancer.

· J Pathol · 2015 · PMID 25424858 · validated civic_curation pubmed

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

· Cancer Res · 2008 · PMID 18829560 · validated civic_curation pubmed

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

· PLoS One · 2011 · PMID 22194965 · validated civic_curation pubmed

Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.

· Gynecol Oncol · 2005 · PMID 15790433 · validated civic_curation pubmed

Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.

· Oncotarget · 2015 · PMID 26304929 · validated civic_curation pubmed

Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974.

· Proc Natl Acad Sci U S A · 2013 · PMID 24277854 · validated civic_curation pubmed

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.

· Breast Cancer Res · 2009 · PMID 19874578 · validated civic_curation pubmed

HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat.

· J Pathol Clin Res · 2016 · PMID 27499916 · validated civic_curation pubmed

Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma.

· Proc Natl Acad Sci U S A · 2012 · PMID 22203985 · validated civic_curation pubmed

Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression.

· Oncotarget · 2015 · PMID 26204491 · validated civic_curation pubmed

Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.

· Oncotarget · 2017 · PMID 28947956 · validated civic_curation pubmed

Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.

· PLoS One · 2016 · PMID 27391784 · validated civic_curation pubmed

Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.

· Oncotarget · 2016 · PMID 26689995 · validated civic_curation pubmed

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.

· Br J Cancer · 2007 · PMID 17224927 · validated civic_curation pubmed

Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.

· Oncotarget · 2016 · PMID 27286459 · validated civic_curation pubmed

Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.

· PLoS One · 2011 · PMID 22046346 · validated civic_curation pubmed

Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.

· Blood · 2000 · PMID 11050000 · validated civic_curation pubmed

Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.

· Blood · 2006 · PMID 16497971 · validated civic_curation pubmed